Affordable Access

Debate: A subversive view of subsets - a dissident clinician's opinion

Authors
Publisher
BioMed Central
Publication Date
Source
PMC
Keywords
  • Commentary
Disciplines
  • Biology

Abstract

Clinical trialists and statisticians are very wary of subgroup analysis, for good reasons. Clinicians have to deal with situations in which subgroups of patients differ widely from one another in their prognosis and response to treatment. Few trials are large enough to demonstrate convincingly these differences in outcome, but often provide suggestive evidence. Should we ignore this and treat all patients as the same, or should we allow dubious statistical evidence to buttress biological plausibility in making clinical decisions?

There are no comments yet on this publication. Be the first to share your thoughts.